---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039953"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:49:01.147730+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q1 FY2024 revenue up 191% to $0.91M; net loss widens to $2.4M

## Summary
- Revenue + government support income of $0.91M vs $0 in year-ago quarter; sales of goods $0.8M from IFP acquisition.
- Net loss attributable to INBS of $2.4M vs $1.2M; driven by IFP combined results offset by $131,250 fair value gain.
- Cash and equivalents $0.2M as of Sep 30; raised ~$4.378M ($3.35M net) in October 2023 public offering.
- Expanded into New Zealand and South America (TSCOM SPA distribution deal); added eight new Australian customers.
- Completed development milestone for ketamine and tramadol assays; ISO 13485:2016 recertified.

## SEC filing metadata
- accession: 0001493152-23-039953
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/0001493152-23-039953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039953
- JSON: https://secwatch.observer/filing/0001493152-23-039953.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039953.txt

## Key facts
- Earnings Releases
  INTELLIGENT BIO SOLUTIONS INC. reported fiscal first quarter ended September 30, 2023 results: revenue combined revenue and government support income increased by 191% to $0.91 million, net income Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million.
  - Period: fiscal first quarter ended September 30, 2023
  - Revenue: combined revenue and government support income increased by 191% to $0.91 million
  - Net income: Net loss attributable to INBS for the first fiscal quarter ended September 30, 2023 was $2.4 million
  - Result: reported results
  source text: The Company’s combined revenue and government support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/0001493152-23-039953-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.